Lilly vows appeal of Alimta patent ruling in Germany

Eli Lilly will try to overturn the German Court of Appeal's ruling that its vitamin regimen patent for Alimta (pemetrexed) will not be infringed when Actavis launches a dipotassium salt form of pemetrexed after the cancer drug's compound patent expires in Germany in December.